Syndax Pharmaceuticals Inc (1T3.SG)
| Previous Close | 20.20 |
| Open | 20.20 |
| Bid | 20.20 x 0 |
| Ask | 20.80 x 0 |
| Day's Range | 20.20 - 20.20 |
| 52 Week Range | 10.50 - 22.60 |
| Volume | |
| Avg. Volume | 34 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | May 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PR NewswireSyndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its first quarter 2024 financial results and provide a business update on Wednesday, May 8, 2024.
PR NewswireSyndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a fireside chat at the at Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024, at 11:00 a.m. ET.
PR NewswireSyndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
Syndax Pharmaceuticals (NASDAQ: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the presentation of positive data from the pivotal AUGMENT-101 trial in pediatric patients with relapsed/refractory (R/R) KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) treated with revumenib, a first-in-class menin inhibitor. The pediatric data was featured in a Plenary Session titled "Pivotal Phase 2 R
